DOCSLIB.ORG

IPCC Newsletter Editor: Edel O’Toole, MB, Phd, FRCP, FRCPI Vol 15, No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IPCC Newsletter Editor: Edel O’Toole, MB, Phd, FRCP, FRCPI Vol 15, No Fighting for a cure. Connecting & helping patients. Empowering research. IPCC Newsletter Editor: Edel O’Toole, MB, PhD, FRCP, FRCPI Vol 15, No. 1 Jan-Feb-Mar 2018 PC PROJECT WORKING TOGETHER WHY IS THE SKIN OF OUR FOR PC PATIENTS PALMS AND SOLES SO MUCH THICKER? The PC Project continues to provide services to Dr Anissa Chikh, Dr Thivi patients with pachyonychia congenita. In this Maruthappu and Prof David P Kelsell, Centre for Cell newsletter, we update you on new developments at Biology and Cutaneous Research, Blizard Institute, PC Project including data from the patient registry, Queen Mary University of London, London new publications, a profile of Pierre Coulombe from our Medical and Scientific Advisory Board and an Keratinocyte hyperproliferation and inflammation are update on development of topical rapamycin as a common to many skin disorders such as psoriasis, treatment for PC. atopic eczema and palmoplantar keratodermas (PPKs) including Pachyonychia Congenita (PC). The The key programs of PC Project are: PPKs are characterised by different patterns of hyperproliferative thickening of the palms and soles, The IPCRR (patient registry) founded in 2004 it and can often exhibit painful callous formation. is one of the most important achievements of PC Previously, the Kelsell group showed that inherited Project with over 700 PC patients now enrolled dominant mutations in RHBDF2, the gene encoding in 47 countries. iRHOM2, are the genetic basis of the inherited syndrome Tylosis with Oesophageal Cancer (TOC) The International PC Consortium (IPCC) to characterised by the development of a painful encourage and support collaborative research keratoderma in childhood and a 95% likelihood of efforts to find a treatment for PC. developing Oesophageal cancer >65 years old. Newsletters both for patients and for the IPCC The group recently published their research in members to inform and unite these communities. Nature Communications 2017, and described an important role for iRHOM2 as a master regulator of Annual PC Patient Support Meetings (PSM) stress responses in skin. They identified that where patients meet, teach and support one iRHOM2 is a novel regulator of the cytoskeletal another and effectively defeat the overwhelming response to physical stress through its interaction loneliness caused by an ultra rare disease. with keratin 16 (K16) in humans and mice. This has important implications for PPKs, wound healing, Publications to continue to bring attention to PC Thivi Anissa David and explain the debilitating nature of this disorder, emphasize the need for treatment and highlight important research achievements. Pachyonychia.org website with accurate and current information on all things related to PC. PC Project wants to express its deep gratitude for each of you - our dear friends old and new. Thank you for all you do to help PC Project, PC Patients and in moving PC research forward. PO Box 17850, Holladay, UT 84117 · www.pachyonychia.org · 801-987-8758 · [email protected] Page 2 IPCC Newsletter Jan-Feb-Mar 2018 Vol 15, No 1 inflammatory skin disease and cancers. They Upon joining the faculty and setting my independent showed that iRHOM2 regulates thickening of the research program at Johns Hopkins University in footpad epidermis where TOC-associated iRHOM2 1992, I decided to focus my efforts on understanding is characterized by palmoplantar thickening, the properties and roles of keratins 6, 16, and 17 upregulates K16 with robust downregulation of its (K6, K16, K17). I made this choice because these type II keratin binding partner K6. In contrast, genes were known to be upregulated following iRHOM2 loss results in reduced K16 expression and tissue injury and also in chronic skin diseases such rhbdf2-/- mice have a thinner epidermis in the as psoriasis and cancer, and relatively little was footpad compared to control mice. These findings known about the associated significance. The shed light on a novel role for iRHOM2 in regulating discovery of mutations in those specific keratin the epithelial stress response and contribute to our genes as the underlying cause for pachyonychia understanding of the molecular mechanisms congenita, reported in 1995, alerted us to new and underlying hyperproliferation of the palmoplantar important ways with which we could study these epidermis in both physiological and disease states. genes and their protein products. Moreover, as PC can be caused by mutations in Keratin 6 and 16, it could be intriguing to determine Without a doubt the birth of the Pachyonychia the contribution of iRHOM2, and its interaction with Congenita Project, circa 2003, has had an enabling these particular keratins in the development of and powerful impact on our research directions and keratoderma in PC. efforts. The opportunity to interact with Mary Schwartz, with other researchers with a direct or References: Maruthappu T, Chikh A, Fell B, peripheral interest in PC, and most especially with Delaney PJ, Brooke MA, Levet C, Moncada-Pazos individuals who live with this condition has been and A, Ishida-Yamamoto A, Blaydon D, Waseem A, continues to be a very inspiring and rewarding Leigh IM, Freeman M, Kelsell DP. Rhomboid family experience. I am so impressed with the PC Project, member 2 regulates cytoskeletal stress-associated and am immensely grateful for the opportunity to be Keratin 16. Nat Commun. 2017 Jan 27;8:14174. part of it. doi: 10.1038/ncomms14174 UPDATE ON PC PROJECT AND PALVELLA’S EFFORTS TO RAPIDLY ADVANCE NOVEL, HIGH STRENGTH IPCC SPOTLIGHT: PIERRE COULOMBE, PHD OPICAL APAMYCIN TO ATIENTS G. Carl Huber Professor and Chair, Department of Cell T R PC P and Development Biology, University of Michigan Medical Wes Kaupinen, Palvella School, PC Project MSAB With the enthusiastic and ever- I grew up in Montréal, Canada and willing help of PC Project and am a first generation scientist. As a scientists and clinicians PhD graduate student at the worldwide, Palvella Therapeutics Université de Montréal I developed continues to make meaningful a passion for the biology of progress on its development of an epithelial tissues by studying the enhanced formulation of topical response of the pulmonary rapamycin to be evaluated in a apparatus to experimental injury. Phase 2/3 safety and efficacy For postdoctoral training I joined a study commencing in 2018. The study builds on the laboratory headed by Dr. Elaine Fuchs at the compelling scientific rationale of rapamycin in PC University of Chicago, Illinois, hoping to decipher the first elucidated by Dr. Roger Kaspar and the mechanisms of epithelial differentiation in the TransDerm team, as well as the early directional epidermis of the skin. While in Dr. Fuchs lab, I clinical evidence generated from the oral rapamycin contributed to a reverse genetics-style effort that study and multiple topical rapamycin studies in PC. resulted in the discovery of the first set of mutations This study will be the first properly designed and in a keratin gene, namely K14, as causative agents adequately powered study to evaluate the efficacy of for the rare disease epidermolysis bullosa simplex. topical rapamycin in pachyonychia congenita. PO Box 17850, Holladay, UT 84117 · www.pachyonychia.org · 801-987-8758 · [email protected] IPCC Newsletter Jan-Feb-Mar 2018 Vol 15, No 1 Page 3 While the TransDerm team discovered certain be most valuable to PC patients. We look forward to proposed direct mechanisms of action in keeping everyone updated on the exciting progress. pachyonychia congenita (Hickerson et al., Journal of Dermatological Science, 2009), further therapeutic Philip Gard, MBChB effects of rapamycin in PC are likely derived from its IPCC Steering Commit- tee Member and PC known anti-inflammatory properties (Weichhart et al, Project Medical and Nature Reviews, 2015) and anti-angiogenic Scientific Advisory properties (Guba et al, Nature Medicine, 2002), each Board Member of which are important given the documented Jonathan K. Wilkin, inflammation and hyper-neovascularization MD, Founding Director, Division of Dermatolo- (Polydefkis et al, Pain, 2016) which are likely major gy and Dental Prod- contributors to PC disease pathogenesis. Phil Jonathan ucts, FDA Palvella’s efforts over the last several months have been acutely focused on two areas: i) Development of a high strength and rigorously tested formulation UPCOMING PC & EB PL-PFDD MEETING of topical rapamycin that has product attributes that are acceptable to both PC patients and global PC Project will participate in an Externally-led regulatory authorities; and ii) Careful selection of Patient-Focused Drug Development Meeting (EL- efficacy outcomes measures, i.e. endpoints, for PFDD) with FDA officials. inclusion into the clinical study. Endpoint selection is by no means trivial for PC given the multi-factorial This FDA meeting will take place the morning of presentation of the disease as well as the scarcity of April 6, at the College Park Marriott Hotel in clinical studies in PC, i.e. limited precedent from Hyattsville, MD, near FDA headquarters. which to work. Palvella has recruited some of the Approximately 50-75 PC patients and caregivers will world’s leading clinical trial design experts, including share their voices through panel presentations, the former Director of the FDA’s Dermatology electronic polling and moderated audience Division, to help address this issue. The clinical discussions. (After a shared luncheon with PC relevance of a narrowed list of potential efficacy patients, EB and EBS patients will have a similar endpoints, many of which are designed to meeting in the afternoon.) objectively evaluate function and ambulation in PC, have now been validated through survey work The Patient’s voice has historically been absent from directly with PC patients. Next steps for Palvella the drug development process until a drug was include proper interactions with regulatory approved by the FDA or when a clinical trial was authorities before initiating the clinical study later this failing and the FDA wanted input from actual year. patients to understand the problem. Now, the FDA wants to hear patient voices at the beginning of the Thanks to everyone who has been a contributor to process and throughout.
Load more

Recommended publications
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Supplementary File 2A Revised
    Supplementary file 2A. Differentially expressed genes in aldosteronomas compared to all other samples, ranked according to statistical significance. Missing values were not allowed in aldosteronomas, but to a maximum of five in the other samples. Acc UGCluster Name Symbol log Fold Change P - Value Adj. P-Value B R99527 Hs.8162 Hypothetical protein MGC39372 MGC39372 2,17 6,3E-09 5,1E-05 10,2 AA398335 Hs.10414 Kelch domain containing 8A KLHDC8A 2,26 1,2E-08 5,1E-05 9,56 AA441933 Hs.519075 Leiomodin 1 (smooth muscle) LMOD1 2,33 1,3E-08 5,1E-05 9,54 AA630120 Hs.78781 Vascular endothelial growth factor B VEGFB 1,24 1,1E-07 2,9E-04 7,59 R07846 Data not found 3,71 1,2E-07 2,9E-04 7,49 W92795 Hs.434386 Hypothetical protein LOC201229 LOC201229 1,55 2,0E-07 4,0E-04 7,03 AA454564 Hs.323396 Family with sequence similarity 54, member B FAM54B 1,25 3,0E-07 5,2E-04 6,65 AA775249 Hs.513633 G protein-coupled receptor 56 GPR56 -1,63 4,3E-07 6,4E-04 6,33 AA012822 Hs.713814 Oxysterol bining protein OSBP 1,35 5,3E-07 7,1E-04 6,14 R45592 Hs.655271 Regulating synaptic membrane exocytosis 2 RIMS2 2,51 5,9E-07 7,1E-04 6,04 AA282936 Hs.240 M-phase phosphoprotein 1 MPHOSPH -1,40 8,1E-07 8,9E-04 5,74 N34945 Hs.234898 Acetyl-Coenzyme A carboxylase beta ACACB 0,87 9,7E-07 9,8E-04 5,58 R07322 Hs.464137 Acyl-Coenzyme A oxidase 1, palmitoyl ACOX1 0,82 1,3E-06 1,2E-03 5,35 R77144 Hs.488835 Transmembrane protein 120A TMEM120A 1,55 1,7E-06 1,4E-03 5,07 H68542 Hs.420009 Transcribed locus 1,07 1,7E-06 1,4E-03 5,06 AA410184 Hs.696454 PBX/knotted 1 homeobox 2 PKNOX2 1,78 2,0E-06
    [Show full text]
  • 140503 IPF Signatures Supplement Withfigs Thorax
    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.
    [Show full text]
  • Index Mutated* Normal* FC P Value FDR** Probe Set Description Gene Symbol
    Index Mutated* Normal* FC P value FDR** Probe set Description Gene symbol 113 1342 128 10,52 0,000503 0,240 202018_s_at Lactotransferrin LTF 616 362 46,7 7,76 0,003493 0,308 237395_at Cytochrome P450, family 4, subfamily Z, polypeptide 1 CYP4Z1 3073 1009 142 7,10 0,021674 0,385 206378_at Secretoglobin, family 2A, member 2 SCGB2A2 376 119 17,7 6,68 0,001962 0,284 214451_at Transcription factor AP-2 beta TFAP2B 578 337 60,5 5,57 0,003174 0,300 227702_at Cytochrome P450, family 4, subfamily X, polypeptide 1 CYP4X1 146 210 38,4 5,47 0,000669 0,244 219768_at V-set domain containing T cell activation inhibitor 1 VTCN1 86 129 24,2 5,31 0,000327 0,201 204607_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) HMGCS2 2613 78,7 15,9 4,95 0,017744 0,371 205358_at Glutamate receptor, ionotropic, AMPA 2 GRIA2 116 23,2 4,83 4,81 0,000513 0,240 203908_at Solute carrier family 4, sodium bicarbonate cotransporter, member 4 SLC4A4 117 79,4 18,0 4,42 0,000518 0,240 239723_at Solute carrier family 40 (iron-regulated transporter), member 1 SLC40A1 625 56,6 13,0 4,34 0,003549 0,308 1553394_a_atTranscription factor AP-2 beta TFAP2B 413 148 34,6 4,28 0,002175 0,286 240304_s_at Transmembrane channel-like 5 TMC5 5181 216 50,9 4,25 0,039946 0,421 223864_at Ankyrin repeat domain 30A ANKRD30A 179 446 106 4,21 0,000826 0,244 223315_at Netrin 4 NTN4 246 120 29,2 4,12 0,001128 0,251 210096_at Cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1 1043 312 80,2 3,89 0,006080 0,319 204041_at Monoamine oxidase B MAOB 192 44,1 11,6 3,80 0,000899 0,244
    [Show full text]
  • Proteomic Expression Profile in Human Temporomandibular Joint
    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
    [Show full text]
  • 1 No. Affymetrix ID Gene Symbol Genedescription Gotermsbp Q Value 1. 209351 at KRT14 Keratin 14 Structural Constituent of Cyto
    1 Affymetrix Gene Q No. GeneDescription GOTermsBP ID Symbol value structural constituent of cytoskeleton, intermediate 1. 209351_at KRT14 keratin 14 filament, epidermis development <0.01 biological process unknown, S100 calcium binding calcium ion binding, cellular 2. 204268_at S100A2 protein A2 component unknown <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 3. 33323_r_at SFN stratifin/14-3-3σ binding <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 4. 33322_i_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 5. 201820_at KRT5 keratin 5 filament, epidermis development <0.01 structural constituent of cytoskeleton, intermediate 6. 209125_at KRT6A keratin 6A filament, ectoderm development <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 7. 209260_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 8. 213680_at KRT6B keratin 6B filament, ectoderm development <0.01 receptor activity, cytosol, integral to plasma membrane, cell surface receptor linked signal transduction, sensory perception, tumor-associated calcium visual perception, cell 9. 202286_s_at TACSTD2 signal transducer 2 proliferation, membrane <0.01 structural constituent of cytoskeleton, cytoskeleton, intermediate filament, cell-cell adherens junction, epidermis 10. 200606_at DSP desmoplakin development <0.01 lectin, galactoside- sugar binding, extracellular binding, soluble, 7 space, nucleus, apoptosis, 11. 206400_at LGALS7 (galectin 7) heterophilic cell adhesion <0.01 2 S100 calcium binding calcium ion binding, epidermis 12. 205916_at S100A7 protein A7 (psoriasin 1) development <0.01 S100 calcium binding protein A8 (calgranulin calcium ion binding, extracellular 13.
    [Show full text]
  • Transcriptome Profiling and Differential Gene Expression In
    G C A T T A C G G C A T genes Article Transcriptome Profiling and Differential Gene Expression in Canine Microdissected Anagen and Telogen Hair Follicles and Interfollicular Epidermis Dominique J. Wiener 1,* ,Kátia R. Groch 1 , Magdalena A.T. Brunner 2,3, Tosso Leeb 2,3 , Vidhya Jagannathan 2 and Monika M. Welle 3,4 1 Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Science, Texas A&M University, College Station, TX 77843, USA; [email protected] 2 Institute of Genetics, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; [email protected] (M.A.T.B.); [email protected] (T.L.); [email protected] (V.J.) 3 Dermfocus, Vetsuisse Faculty, University Hospital of Bern, 3010 Bern, Switzerland; [email protected] 4 Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland * Correspondence: [email protected]; Tel.: +1-979-862-1568 Received: 30 June 2020; Accepted: 3 August 2020; Published: 4 August 2020 Abstract: The transcriptome profile and differential gene expression in telogen and late anagen microdissected hair follicles and the interfollicular epidermis of healthy dogs was investigated by using RNAseq. The genes with the highest expression levels in each group were identified and genes known from studies in other species to be associated with structure and function of hair follicles and epidermis were evaluated. Transcriptome profiling revealed that late anagen follicles expressed mainly keratins and telogen follicles expressed GSN and KRT15. The interfollicular epidermis expressed predominately genes encoding for proteins associated with differentiation. All sample groups express genes encoding for proteins involved in cellular growth and signal transduction.
    [Show full text]
  • UCLA Electronic Theses and Dissertations
    UCLA UCLA Electronic Theses and Dissertations Title Proteomic Analysis of Cancer Cell Metabolism Permalink https://escholarship.org/uc/item/8t36w919 Author Chai, Yang Publication Date 2013 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA Los Angeles Proteomic Analysis of Cancer Cell Metabolism A thesis submitted in partial satisfaction of the requirements of the degree Master of Science in Oral Biology by Yang Chai 2013 ABSTRACT OF THESIS Proteomic Analysis of Cancer Cell Metabolism by Yang Chai Master of Science in Oral Biology University of California, Los Angeles, 2013 Professor Shen Hu, Chair Tumor cells can adopt alternative metabolic pathways during oncogenesis. This is an event characterized by an enhanced utilization of glucose for rapid synthesis of macromolecules such as nucleotides, lipids and proteins. This phenomenon was also known as the ‘Warburg effect’, distinguished by a shift from oxidative phosphorylation to increased aerobic glycolysis in many types of cancer cells. Increased aerobic glycolysis was also indicated with enhanced lactate production and glutamine consumption, and has been suggested to confer growth advantage for proliferating cells during oncogenic transformation. Development of a tracer-based ii methodology to determine de novo protein synthesis by tracing metabolic pathways from nutrient utilization may certainly enhance current understanding of nutrient gene interaction in cancer cells. We hypothesized that the metabolic phenotype of cancer cells as characterized by nutrient utilization for protein synthesis is significantly altered during oncogenesis, and 13C stable isotope tracers may incorporate 13C into non-essential amino acids of protein peptides during de novo protein synthesis to reflect the underlying mechanisms in cancer cell metabolism.
    [Show full text]
  • Cytokeratin 6B Polyclonal Antibody Catalog Number:17391-1-AP 1 Publications
    For Research Use Only Cytokeratin 6B Polyclonal antibody www.ptglab.com Catalog Number:17391-1-AP 1 Publications Catalog Number: GenBank Accession Number: Purification Method: Basic Information 17391-1-AP BC034535 Antigen affinity purification Size: GeneID (NCBI): Recommended Dilutions: 150ul , Concentration: 400 μg/ml by 3854 WB 1:1600-1:5000 Nanodrop and 213 μg/ml by Bradford Full Name: IP 0.5-4.0 ug for IP and 1:500-1:1000 method using BSA as the standard; keratin 6B for WB Source: IHC 1:50-1:500 Calculated MW: IF 1:200-1:800 Rabbit 564 aa, 60 kDa Isotype: Observed MW: IgG 60 kDa Immunogen Catalog Number: AG11288 Applications Tested Applications: Positive Controls: FC, IF, IHC, IP, WB,ELISA WB : mouse skin tissue, A431 cells, rat skin tissue Cited Applications: IP : mouse skin tissue, IHC IHC : human lung cancer tissue, human cervical cancer Species Specificity: tissue, human breast cancer tissue, human tonsil human, mouse, rat tissue, human oesophagus tissue Cited Species: mouse IF : HeLa cells, Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 Keratins are a large family of proteins that form the intermediate filament cytoskeleton of epithelial cells, which Background Information are classified into two major sequence types. Type I keratins are a group of acidic intermediate filament proteins, including K9-K23, and the hair keratins Ha1-Ha8. Type II keratins are the basic or neutral courterparts to the acidic type I keratins, including K1-K8, and the hair keratins, Hb1-Hb6.
    [Show full text]
  • Pachyonychia Congenita
    PHOTO QUIZ What Is Your Diagnosis? A 9-year-old boy presented with dystrophic nails and follicular hyperkeratosis. PLEASE TURN TO PAGE 143 FOR DISCUSSION Dirk M. Elston, MD, Departments of Dermatology and Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania. 104 CUTIS® Photo Quiz Discussion The Diagnosis: Pachyonychia Congenita achyonychia congenita (PC) is an autosomal- not undergo malignant degeneration, but squamous dominant form of ectodermal dysplasia char- cell carcinoma has been reported in chronic plan- P acterized by nail dystrophy, follicular keratotic tar ulcerations of PC.4 Patients with PC1 lack the spines, and focal palmoplantar keratoderma. epidermal cysts seen in type II PC (PC2). Type I PC (PC1), also known as the Jadassohn- PC2, also known as Jackson-Lawler syndrome, Lewandowski syndrome, is associated with muta- is associated with epidermal or pilosebaceous cysts, tions in the keratin 16 or keratin 6a genes.1,2 palmoplantar bullae, hyperhidrosis, natal teeth, Similar mutations also can cause focal palmoplan- twisted hair, and mutations in the keratin 17 gene. tar keratoderma alone, without other manifesta- The cysts associated with PC2 predominantly tions of PC. PC1 is associated with oral lesions affect the upper trunk and resemble steatocystoma similar to white sponge nevus and, rarely, laryngeal multiplex or eruptive vellus hair cysts. Keratin 17 leukokeratosis, which can lead to severe respiratory mutations also can manifest solely as steatocys- distress.3 The oral lesions associated with PC do toma multiplex with little or no nail dystrophy.5 VOLUME 72, AUGUST 2003 143 Photo Quiz Discussion PC2 also has been described with mutations in the 3.
    [Show full text]
  • Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network
    The Journal of Immunology Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network Kai H. Ha¨nel,*,†,1,2 Carolina M. Pfaff,*,†,1 Christian Cornelissen,*,†,3 Philipp M. Amann,*,4 Yvonne Marquardt,* Katharina Czaja,* Arianna Kim,‡ Bernhard Luscher,€ †,5 and Jens M. Baron*,5 Atopic dermatitis, a chronic inflammatory skin disease with increasing prevalence, is closely associated with skin barrier defects. A cy- tokine related to disease severity and inhibition of keratinocyte differentiation is IL-31. To identify its molecular targets, IL-31–dependent gene expression was determined in three-dimensional organotypic skin models. IL-31–regulated genes are involved in the formation of an intact physical skin barrier. Many of these genes were poorly induced during differentiation as a consequence of IL-31 treatment, resulting in increased penetrability to allergens and irritants. Furthermore, studies employing cell-sorted skin equivalents in SCID/NOD mice demonstrated enhanced transepidermal water loss following s.c. administration of IL-31. We identified the IL-1 cytokine network as a downstream effector of IL-31 signaling. Anakinra, an IL-1R antagonist, blocked the IL-31 effects on skin differentiation. In addition to the effects on the physical barrier, IL-31 stimulated the expression of antimicrobial peptides, thereby inhibiting bacterial growth on the three-dimensional organotypic skin models. This was evident already at low doses of IL-31, insufficient to interfere with the physical barrier. Together, these findings demonstrate that IL-31 affects keratinocyte differentiation in multiple ways and that the IL-1 cytokine network is a major downstream effector of IL-31 signaling in deregulating the physical skin barrier.
    [Show full text]
  • Transcriptomic Insight Into the Translational Value of Two Murine
    www.nature.com/scientificreports OPEN Transcriptomic insight into the translational value of two murine models in human atopic dermatitis Young‑Won Kim1,5, Eun‑A Ko2,5, Sung‑Cherl Jung2, Donghee Lee1, Yelim Seo1, Seongtae Kim1, Jung‑Ha Kim3, Hyoweon Bang1, Tong Zhou4* & Jae‑Hong Ko1* This study sought to develop a novel diagnostic tool for atopic dermatitis (AD). Mouse transcriptome data were obtained via RNA‑sequencing of dorsal skin tissues of CBA/J mice afected with contact hypersensitivity (induced by treatment with 1‑chloro‑2,4‑dinitrobenzene) or brush stimulation‑ induced AD‑like skin condition. Human transcriptome data were collected from German, Swedish, and American cohorts of AD patients from the Gene Expression Omnibus database. edgeR and SAM algorithms were used to analyze diferentially expressed murine and human genes, respectively. The FAIME algorithm was then employed to assign pathway scores based on KEGG pathway database annotations. Numerous genes and pathways demonstrated similar dysregulation patterns in both the murine models and human AD. Upon integrating transcriptome information from both murine and human data, we identifed 36 commonly dysregulated diferentially expressed genes, which were designated as a 36‑gene signature. A severity score (AD index) was applied to each human sample to assess the predictive power of the 36‑gene AD signature. The diagnostic power and predictive accuracy of this signature were demonstrated for both AD severity and treatment outcomes in patients with AD. This genetic signature is expected to improve both AD diagnosis and targeted preclinical research. Patients with atopic dermatitis (AD) ofen exhibit an itchy rash, xerosis, skin barrier defects, chronic relapses, and emotional distress, which reduces their quality of life1.
    [Show full text]